Significant Lightening Effect Of A Whitening Formula (Aebritening Complex-01) Compared To 4% Hydroxyquinone

Introduction: Fair skin complexion is much preferred by the Asian population. Four percent hydroquinone has been known to be effective as a whitening agent albeit unwanted effects such as worsening pigmentation, onchronosis and irritation have been well documented. This study aims to compare the lightening effects and the safety profile of a novel topical formulation derived from Vitamin C in combination with plant’s extract ,known as AEBritening Complex- 01 with a standard formulation containing four percent Hydroquinone. Material & Method: A case control study was conducted to evaluate the efficacy of AEBritening Complex-01 versus 4% Hydroquinone cream in lightening normal skin colour. AEBritening Complex-01* contains refined stabilized vitamin C Complex and plant’s extract as active ingredient . All 20 subjects were applied with AEBritening Complex-01 on their right arm , 4% hydroquinone on their left arm twice a day for 28 days. Their left forearm were left untreated. Visual and colorimeter assessment of the right arm, left arm and left forearm were done on day 0, Day7, Day 14, Day 21 and Day 28. Results: Skin areas treated with AEBritening Complex-01 showed significant degree of lightening effect (+1.69) after 21 days of treatment compared to areas treated with 4% hydroquinone (+0.47) and untreated area (+0.13). This was tested using using Skin Colorimeter Konica Minolta CR 10. There was further improvement at day 28 of the treated area with AEBritening Complex-01 (+1.96), 4% hydroquinone (+0.66) and untreated area (-0.09). The AEBritening Complex-01 formulation showed significant skin lightening effect compared to standard 4 % Hydroxyquinone with p< 0.05. Conclusion: The AEBrightening Complex-01 formulation is significantly effective to lighten normal skin colour compared to 4% Hydroquinone.

The triad of lichen planus, thymoma and liver cirrhosis-hepatoma. First reported case.

We describe a patient with liver cirrhosis who presented with erosive oral and cutaneous lichen planus (LP) and incidentally was found simultaneously to have thymoma and hepatoma. We support the notion forwarded earlier that LP and chronic liver disease is more than a mere coincidence and that there is a non-coincidental association between LP and thymoma. We believe this is also the first reported case in the English Literature of coexistence of the three condition LP, thymoma and hepatoma complicating liver disease.

Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis.

OBJECTIVE: An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis. METHODOLOGY: Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 microg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 microg by metered dose inhaler and 500 microg by a nebulizer. RESULTS: The results showed a significant improvement from baselines (mean percentage change +/- SD) of peak expiratory flow rate (PEF) by 8.5 +/- 8.72% and 15.3 +/- 11.63%, forced expiratory volume in 1 s (FEV1) by 8.77 +/- 9.69% and 10.2 +/- 12.2% and forced vital capacity (FVC) by 10.25 +/- 11.61% and 10.09 +/- 10.88% after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEE FEV1 and FVC were 9.89 +/- 9.35% and 14.39 +/- 12.82%, 9.38 +/- 10.41% and 13.52 +/- 17.09%, and 8.03 +/- 10.85% and 9.63 +/- 13.85%, respectively. Eleven patients (45.8%) responded to one or both bronchodilators significantly (> 15% improvement in FEV1). Five patients (20%) responded to both, three (12%) to fenoterol alone and another three (12%) to ipratropium bromide alone. CONCLUSION: There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2%).

Penicillium marneffei infection in a non aids patient: first case report from Malaysia.

Penicillium marneffei, a dimorphic fungus is a rare opportunistic pathogen. It is known to cause infection in immunocompromised patients and recently its occurrence in AIDS patients has been well-documented. Disease with Penicillium marneffei is even rarer among previously healthy individuals. The disease is endemic in Southeast Asia and China. Recognition of this rare disease is important because it is amenable to treatment. We report a case of P. marneffei infection in a previously healthy individual.